ADBest TREAT Registry
报名条件（概要）
- 年龄：18 Years – 不限
- 性别：不限
- 健康志愿者：不接受
完整入排标准请以官方页面为准。
开展国家/地区
Germany
药品与企业信息
Oral JAK1 inhibitor administered fot the treatment of atopic dermatitis.
Oral JAK1 inhibitor administered for the treatment of atopic dermatitis.
Oral JAK1 inhibitor administered for the treatment of atopic dermatitis.
Monaclonal antibody targeting IL4 and IL-13 receptors fot the treatment of moderate to severe atopic dermatitis.
Monaclonal antibody targeting IL-13 receptors fot the treatment of moderate to severe atopic dermatitis.
Monoclonal antibody targeting IL31 receptor alpha to inhibit pruritus and inflammation in atopic dermatitis.
Monoclonal antibody neutralizing IL13 specifically for the treatment of atopic dermatitis.
Conventional systemic treatments including traditional immunosuppressants or corticosteroids administrated for moderate to severe atopic dermatitis.
研发企业
试验官方登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
研究简介（原文）
Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life. The disease may be influenced by genetic factors, environmental triggers, epidermal barrier dysfunction, and immune dysregulation. Patients may experience flares triggered by allergens, infections, dry skin, stress, irritants, or other environmental factors. Atopic dermatitis can also be associated with secondary bacterial or viral skin infections and a substantial burden on daily activities, work productivity, sleep, and psychosocial well-being.TREAT is the German national treatment registry for patients with atopic dermatitis. The registry collects real-world data from routine dermatological care to assess disease course, treatment patterns, disease burden, patient-relevant treatment benefits, and quality of life. Data are collected electronically using physician-completed eCRFs and patient-completed questionnaires at inclusion and follow-up visits. The registry aims to improve understanding of atopic dermatitis real-world care and outcomes in daily clinical practice.
适应症
主动联系研究团队
这项试验目前在中国大陆没有研究中心
这种情况下，直接发"入组咨询"往往会被回复"您所在地区没有中心"。更有效的做法是申请同情用药／扩展准入（由主治医生一同提出），或询问能否到最近的境外中心参加。下面已为您切换到对应的信件版本。
查看完整申请路径与成功率说明 →总联系人（申办方／研究总部）
- Matthias Augustin, Prof.Dr.m.augustin@uke.de+4940741055428
研究中心联系方式
- Institute for Health Services Research in Dermatology and Nursing, IVDP; University Medical Center Hamburg-Eppendorf,UKEHamburg，Germany
问自己是否符合条件、如何预筛
我的病情档案
档案只保存在您自己的浏览器里，不会上传，任何人（包括本站）都看不到。
英文版（发给研究团队）
Dear Study Team, I am a patient in China and I am interested in participating in your clinical trial: Study Title: ADBest TREAT Registry ClinicalTrials.gov Identifier: NCT07904546 Sponsor: Universitätsklinikum Hamburg-Eppendorf Investigational product: Abrocitinib, Baricitinib, Upadacitinib, Dupilumab, Lebrikizumab About me: - Age: (please fill in) - Sex: (please fill in) - Confirmed diagnosis and stage: (please fill in) - Biomarkers / genetic testing: not available - Prior and current treatments: (please fill in) - Performance status (ECOG): not assessed - Current location: China - Travel ability: (please fill in) Could you please let me know: 1. Whether I might be eligible for this study; 2. Which site would be closest and most practical for me, and whether remote pre-screening is possible; 3. What documents (medical records, pathology or imaging reports, recent labs) I should prepare for pre-screening. I can provide English translations of my medical records. Thank you very much for your time and help. Kind regards, (your name) (your email / phone with country code)
中文对照（供您核对）
尊敬的研究团队： 我是一位来自中国的患者，希望咨询参加以下临床试验的可能： 研究名称：ADBest TREAT Registry 试验编号：NCT07904546 申办方：Universitätsklinikum Hamburg-Eppendorf 研究药物：Abrocitinib、Baricitinib、Upadacitinib、Dupilumab、Lebrikizumab 我的基本情况： - 年龄：（请填写） - 性别：（请填写） - 确诊疾病与分期：（请填写） - 基因／标志物检测：暂无 - 既往及当前治疗：（请填写） - 体能状态（ECOG）：未评估 - 目前所在城市：中国 - 可前往范围：（请填写） 想请教三个问题： 1. 我是否可能符合本研究的入组标准？ 2. 哪个中心对我最方便可行？能否远程预筛？ 3. 预筛需要准备哪些资料（病历、病理、影像、近期化验）？ 我可以提供英文翻译版病历。感谢您的时间与帮助。 顺祝安康 （您的姓名） （您的邮箱／带国际区号的电话）
提示：请与主治医生一起发信——由医生署名的申请，回复率远高于患者单独发信。首封邮件不要附身份证号等敏感信息。研究团队通常在 3–10 个工作日内回复，两周无回音可礼貌追问一次。
下一步怎么做？
- 把本页信息带给您的主治医生，评估是否适合参加。
- 点击下方按钮打开官方注册页，查看研究中心联系方式。
- 直接联系研究团队咨询报名事宜（通常有中文同声翻译服务可协助沟通）。